NASDAQ:CNATConatus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.79 -0.08 (-2.79 %) (As of 07/14/2020) Add Compare Share Today's Range$2.73Now: $2.79▼$2.9450-Day Range$0.56MA: $3.07▼$4.3052-Week Range$0.23Now: $2.79▼$1.07Volume33,439 shsAverage Volume1.28 million shsMarket Capitalization$92.54 millionP/E RatioN/ADividend YieldN/ABeta1.84 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Conatus Pharmaceuticals. Previous Next 3.3 Community Rank Outperform VotesConatus Pharmaceuticals has received 537 “outperform” votes. (Add your “outperform” vote.)Underperform VotesConatus Pharmaceuticals has received 275 “underperform” votes. (Add your “underperform” vote.)Community SentimentConatus Pharmaceuticals has received 66.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNAT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldConatus Pharmaceuticals does not currently pay a dividend.Dividend GrowthConatus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Conatus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.30% of the stock of Conatus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 15.20% of the stock of Conatus Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Conatus Pharmaceuticals is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Conatus Pharmaceuticals is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConatus Pharmaceuticals has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.66 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNAT Previous Symbol CUSIPN/A CIK1383701 Webwww.conatuspharma.com Phone858-376-2600Debt Debt-to-Equity RatioN/A Current Ratio16.28 Quick Ratio16.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.72 million Price / Sales4.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book5.26Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-11,390,000.00 Net Margins-52.42% Return on Equity-48.22% Return on Assets-39.32%Miscellaneous Employees30 Outstanding Shares33,170,000Market Cap$92.54 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable $2.79 -0.08 (-2.79 %) (As of 07/14/2020) 30 days | 90 days | 365 days | Advanced Chart Receive CNAT News and Ratings via Email Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions How has Conatus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Conatus Pharmaceuticals' stock was trading at $0.3418 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CNAT stock has increased by 716.3% and is now trading at $2.79. View which stocks have been most impacted by Coronavirus. When is Conatus Pharmaceuticals' next earnings date? Conatus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Conatus Pharmaceuticals. How were Conatus Pharmaceuticals' earnings last quarter? Conatus Pharmaceuticals Inc (NASDAQ:CNAT) released its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.10). Conatus Pharmaceuticals had a negative return on equity of 48.22% and a negative net margin of 52.42%. View Conatus Pharmaceuticals' earnings history. Has Conatus Pharmaceuticals been receiving favorable news coverage? Media coverage about CNAT stock has been trending very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Conatus Pharmaceuticals earned a daily sentiment score of -3.6 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future. View the latest news about Conatus Pharmaceuticals. Who are some of Conatus Pharmaceuticals' key competitors? Some companies that are related to Conatus Pharmaceuticals include ANI Pharmaceuticals (ANIP), Albireo Pharma (ALBO), Ovid Therapeutics (OVID), Fulcrum Therapeutics (FULC), Axovant Sciences (AXON), CymaBay Therapeutics (CBAY), Tiziana Life Sciences (TLSA), Progenics Pharmaceuticals (PGNX), MannKind (MNKD), Passage Bio (IMRA), Beyondspring (BYSI), AMAG Pharmaceuticals (AMAG), Geron (GERN), Calithera Biosciences (CALA) and CytomX Therapeutics (CTMX). View all competitors. What other stocks do shareholders of Conatus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), Cascadian Therapeutics (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Novavax (NVAX), Dextera Surgical (DXTR), Geron (GERN) and Verastem (VSTM). Who are Conatus Pharmaceuticals' key executives? Conatus Pharmaceuticals' management team includes the following people: Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications What is Conatus Pharmaceuticals' stock symbol? Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT." How do I buy shares of Conatus Pharmaceuticals? Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Conatus Pharmaceuticals' stock price today? One share of CNAT stock can currently be purchased for approximately $2.79. How big of a company is Conatus Pharmaceuticals? Conatus Pharmaceuticals has a market capitalization of $92.54 million and generates $21.72 million in revenue each year. Conatus Pharmaceuticals employs 30 workers across the globe. What is Conatus Pharmaceuticals' official website? The official website for Conatus Pharmaceuticals is www.conatuspharma.com. How can I contact Conatus Pharmaceuticals? Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
